HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024
Shots:
- HUTCHMED has reported the P-III (ESLIM‑01) study data of sovleplenib (oral) vs PBO in primary Immune Thrombocytopenia (ITP) adults (n=188) previously treated with at least one line of standard therapy in China and will highlight data of HMPL-306, HMPL-760 & tazemetostat at EHA 2024
- The study depicted a durable response rate of 48.4% vs 0%, median TTR of 1.1wks., improved physical functioning & energy/fatigue plus a tolerable safety profile with grade ≥3 TEAEs in 25.4% (sovleplenib) vs 24.2% (PBO) of patients
- The company will also present the P-II data from P-II/III (ESLIM-02) trial of sovleplenib vs PBO to treat warm antibody autoimmune hemolytic anemia (wAIHA), showing ORR of 43.8% vs 0% at 8wks. & 66.7% at 24wks. with a favorable safety profile
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Reports NDA Acceptance with Priority Review by the US FDA for Sovleplenib to Treat Primary Immune Thrombocytopenia (PIT)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
